Switch theme
Sign up to access all valuation multiples
Oneness Biotech Co Ltd is a Taiwan based biopharmaceutical company. The company develops healthcare drugs. Its products are used for chronic diabetic, dengue hemorrhagic fever, and Rheumatoid Arthritis. The company's operating segment includes New Drug Research and Development and Agricultural Products Cultivation. It generates maximum revenue from New Drug Research and Development segment.
2008
n/a
LTM Revenue n/a
LTM EBITDA n/a
$653M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oneness Biotech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Oneness Biotech achieved revenue of $3.6M and an EBITDA of -$20.7M.
Oneness Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oneness Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.6M | $3.6M | XXX | XXX | XXX |
| Gross Profit | $25.5M | $1.0M | XXX | XXX | XXX |
| Gross Margin | 973% | 28% | XXX | XXX | XXX |
| EBITDA | -$26.0M | -$20.7M | XXX | XXX | XXX |
| EBITDA Margin | -994% | -581% | XXX | XXX | XXX |
| Net Profit | $10.9M | -$39.6M | XXX | XXX | XXX |
| Net Margin | 415% | -1113% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oneness Biotech's stock price is TWD 59 (or $2).
Oneness Biotech has current market cap of TWD 28.3B (or $853M), and EV of TWD 21.6B (or $653M).
See Oneness Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $653M | $853M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oneness Biotech has market cap of $853M and EV of $653M.
Oneness Biotech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Oneness Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oneness Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $653M | XXX | XXX | XXX |
| EV/Revenue | 183.5x | XXX | XXX | XXX |
| EV/EBITDA | -31.6x | XXX | XXX | XXX |
| P/E | -24.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -54.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOneness Biotech's NTM/LTM revenue growth is n/a
Oneness Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Oneness Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oneness Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oneness Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -581% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 52% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 137% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 784% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 974% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oneness Biotech acquired XXX companies to date.
Last acquisition by Oneness Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Oneness Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oneness Biotech founded? | Oneness Biotech was founded in 2008. |
| Where is Oneness Biotech headquartered? | Oneness Biotech is headquartered in Taiwan. |
| Is Oneness Biotech publicy listed? | Yes, Oneness Biotech is a public company listed on ROCO. |
| What is the stock symbol of Oneness Biotech? | Oneness Biotech trades under 4743 ticker. |
| When did Oneness Biotech go public? | Oneness Biotech went public in 2011. |
| Who are competitors of Oneness Biotech? | Similar companies to Oneness Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oneness Biotech? | Oneness Biotech's current market cap is $853M |
| What is the current revenue growth of Oneness Biotech? | Oneness Biotech revenue growth between 2023 and 2024 was 36%. |
| Is Oneness Biotech profitable? | Yes, Oneness Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
